 |
【Welfare News】 Handok announced this year’s management plan to overcome the Corona 19’fargo’ through’digital transformation’ in open innovation, marketing, sales, and clinical trials.
Handok, which recorded close to 500 billion won in sales and 30 billion won in operating profits last year, is a strategy to secure sustainable competitiveness this year by making quick transformations in marketing tools.
In fact, despite the Corona 19 situation, Handok has already continued to pursue DT work, and as a result, despite the corona pandemic last year, it was a result of not stepping back.
DT, which Handok has been running for many years, has an online seminar symposium in the field of marketing and sales, and E-CRM is also being tried.
In addition, there are smart factories, introduction of SAP to a new level for database construction, introduction of e-solutions for clinical trials, RPA (Robotic Process Automation) project to increase work efficiency, and team building through online meetings.
Chairman Youngjin Kim, Germany<사진>Through these efforts, the company announced its goal of continuing growth in 2021 this year as well in the prescription drugs, generic drugs and consumer health business units, and device and life science business units.
Completion of the research and development outpost Magok R&D Research Center at the end of the year
This year, Handok is expected to be a meaningful year for open innovation. This is because the Magok R&D Research Center, which is being built jointly with Genexine, will be completed in December. Chairman Young-jin Kim explained that the Magok R&D Institute will play an important role in expanding Handok’s open innovation strategy and strengthening research cooperation with Genexine. In addition, it is expected to be reborn as an outpost of research and development for the development of new drugs with global competitiveness and expansion of the pipeline.
As open innovation currently in progress, Genexine and’sustainable growth hormone’, which is being developed, are preparing for a phase 3 clinical trial. In addition, the’Pan-TRK’ inhibitory anticancer drug under development with CMG Pharmaceuticals and the National Anticancer Drug Development Project is undergoing phase 1 clinical trials.
ABL001, an anti-angiogenic anti-cancer antibody under development with ABL Bio, will lead a phase 2 clinical trial for patients with biliary tract cancer by Handok starting this year. In addition, Dinex, a hypertension treatment device developed by Handok Calos Medical, successfully ended the two-year follow-up observation of a clinical trial conducted in Korea in May last year, and has begun recruiting patients from domestic confirmatory clinicians. It is also planning to start multinational clinical trials this year.
Chairman Kim Young-jin said, “The Rapid Screening Test Kit, an in vitro diagnostic device based on nanocon technology, which is being developed with NB POSTECH, a diagnostic medical device, is planning to enter the European market this year.” Is planning to secure overseas markets by challenging the FDA EUA (emergency use approval) this year.”
Handok is also pursuing a strategy to prepare for entry into the domestic as well as overseas markets from the product development stage in R&D. The aforementioned Pan-TRK inhibitory anticancer drugs, Dinex, and Rapid Screening Test Kit are the protagonists.
Also noteworthy is the move of Resolute, which jointly invested with Genexine to strengthen its global competitiveness. Resolute is a bio-venture focusing on the development of innovative treatments related to rare diseases. In October 2020, Resolute succeeded in attracting $41 million (KRW 47.2 billion) in the form of private placement and was listed on NASDAQ.
Handok secured domestic commercial rights for RZ358, an oral plasma kallikrein inhibitor for treatment of macular edema, and RZ358, an oral plasma kallikrein inhibitor for the treatment of macular edema, and strengthened the pipeline for diabetes and rare diseases. RZ358 was designated as a rare pediatric disease drug (RPD) by the US FDA last year. If Resolute gets a new drug license for RZ358, it will receive a priority review voucher that can be applied to other developed drugs.
Continued development and development in the field of specialty medicines and rare diseases
In the specialty drug business, which generated sales of about 300 billion won last year, the company plans to focus on fostering Amaril M, Amaryl MEX, and Tenelia M Seobang. In particular, Tenelia ranked fourth in the DPP-4 treatment market in the second half of last year. This year, Handok aims to achieve sales of over 80 billion won in diabetes business alone this year, based on the experience of diabetes masters.
Handok is also strengthening its competitiveness in the field of rare diseases with differentiated products and marketing. With a solid partnership with global companies in the field of rare diseases such as Alexion, Actelion, Jazz, and Amicus, PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) treatment Soliris, pulmonary arterial hypertension treatment Traclear, Obsumite, Innovative treatments for rare diseases such as Uptravi, Defitelli, a treatment for severe hepatic vein obstruction, and Galafold, the first oral Fabry disease treatment, were introduced in Korea.
This year, we plan to successfully launch Ultomiris following Soliris, continuing our efforts for a better life for PNH patients. The rare disease field is blue ocean, which is growing day by day, and many global pharmaceutical companies are paying attention.
Add excelon to originals such as Abaksim and Allegra
Handok also emphasized the continued expansion of the market share of original products. In 2021, excellent original products such as 4 adult vaccines including Abaksim, a hepatitis A vaccine, and Paxigriptetra, Allegra, an allergic rhinitis treatment, Tobias, an overactive bladder treatment, Zatral, an osteoporosis treatment, and Viviant, and Bonviva, were used to treat osteoporosis. It is being secured. In addition, the addition of Novartis’ Alzheimer’s dementia treatment Excelon and Epilepsy treatment Trireptal recorded a high growth rate last year, but this year, the plan is to continue a greater growth.
The general medicine business unit suffered from Corona 19, but achieved 59.8 billion won in sales in 2020. In particular, major products such as Ketotop, Festal, and Cleartin increased their market share and strengthened their No. 1 position.
Ketotop recorded 7.3% growth, continuously increasing its market share. In addition, as a ketotop hot product, it has also launched a band-type product that reflects consumer needs.
Chairman Kim Young-jin said, “We will continue to introduce convenient products in consideration of the effect of the consumer’s position and the use side.
Ketotop is also receiving good responses in Malaysia and Kazakhstan, and is expected to expand exports as the clinical licensed in Russia last year was successfully completed. Cleartin grew 65.4% year-on-year, and its market share for acne treatments was 64.4%, keeping the overwhelming number one. It is expected that further growth will be possible this year.